Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: THY025
MIFTS: 56

Thymus Cancer

Categories: Cancer diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Thymus Cancer

About this section

MalaCards integrated aliases for Thymus Cancer:

Name: Thymus Cancer 12 42 15
Malignant Neoplasm of Thymus 70 32
Thymus Neoplasms 44 70
Thymus Neoplasm 73 17
Thymic Tumor 12 58
Neoplasm of Thymus 12
Thymoma, Familial 70
Thymic Carcinoma 70
Thymic Neoplasms 54
Thymic Neoplasm 12
Thymoma, Type C 70

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases Genetic diseases
Anatomical: Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:3277
ICD9CM 34 164.0
MeSH 44 D013953
NCIt 50 C4962
SNOMED-CT 67 94096009
ICD10 32 C37
UMLS via Orphanet 71 C3714644
Orphanet 58 ORPHA100100
UMLS 70 C0205969 C0751552 C1322286 more
Sources

Summaries for Thymus Cancer

About this section
MedlinePlus : 42 The thymus is a small organ in your upper chest, under your breastbone. Before birth and during childhood, the thymus helps the body make a type of white blood cell. These cells help protect you from infections. Cancer of the thymus is rare. You are more likely to get it if you have other diseases such as myasthenia gravis, lupus or rheumatoid arthritis. Sometimes there are no symptoms. Other times, thymus cancer can cause A cough that doesn't go away Chest pain Trouble breathing Doctors use a physical exam, imaging tests, and a biopsy to diagnose thymus cancer. The most common treatment is surgery to remove the tumor. Other options include radiation therapy, chemotherapy, and hormone therapy. NIH: National Cancer Institute

MalaCards based summary : Thymus Cancer, also known as malignant neoplasm of thymus, is related to thymic carcinoma and thymoma. An important gene associated with Thymus Cancer is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are ICos-ICosL Pathway in T-Helper Cell and Cell adhesion molecules. The drugs Tubulin Modulators and Antimitotic Agents have been mentioned in the context of this disorder. Affiliated tissues include thymus, lung and liver, and related phenotypes are neoplasm of the thymus and immunodeficiency

Disease Ontology : 12 An immune system cancer located in the thymus.

Wikipedia : 73 A thymoma is a tumor originating from the epithelial cells of the thymus that is considered a rare... more...

Sources

Related Diseases for Thymus Cancer

About this section

Diseases related to Thymus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 491)
# Related Disease Score Top Affiliating Genes
1 thymic carcinoma 32.2 NKX2-1 KRT7 KIT CD5
2 thymoma 31.4 TTN NKX2-1 MIR125A KIT IL2 DPYSL5
3 thymic epithelial tumor 30.7 KIT CD5
4 cortical thymoma 30.5 TTN CD4
5 large cell carcinoma 30.5 NKX2-1 KRT7 KIT
6 neuroendocrine carcinoma 30.5 NKX2-1 KRT7 KIT
7 cavernous hemangioma 30.4 NKX2-1 KRT7 KIT
8 mediastinal cancer 30.4 NKX2-1 KRT7 KIT CD5
9 teratoma 30.4 NKX2-1 KRT7 KIT AKT1
10 lymphoblastic lymphoma 30.4 CD8A CD5 CD4
11 epithelial malignant thymoma 30.4 TTN CD5 AIRE
12 hemangioma 30.4 NKX2-1 KRT7 KIT AKT1
13 lymphoma, mucosa-associated lymphoid type 30.3 ICOSLG CD5 CD4 CCR6
14 myasthenia gravis 30.3 TTN MUSK LRP4 IL2 AIRE
15 good syndrome 11.2
16 ureter adenocarcinoma 10.6 NKX2-1 KRT7
17 cork-handlers' disease 10.5 CD8A CD4
18 necrotic uveal melanoma 10.5 CD8A CD4
19 third ventricle chordoid glioma 10.5 NKX2-1 CD4
20 thymus basaloid carcinoma 10.5 NKX2-1 CD5
21 early yaws 10.5 CD8A CD4
22 adult acute lymphocytic leukemia 10.5 CD8A CD4 CCR6
23 glioblastoma neural subtype 10.5 NKX2-1 IL2
24 ureter small cell carcinoma 10.5 NKX2-1 KRT7
25 ventilation pneumonitis 10.5 CD8A CD4
26 diffuse infiltrative lymphocytosis syndrome 10.5 CD8A CD4
27 cervical adenoid cystic carcinoma 10.5 KRT7 KIT
28 spindle epithelial tumor with thymus-like differentiation tumor 10.5 KIT CD5
29 pneumonic tularemia 10.5 CD8A CD4 CCR6
30 tularemia 10.5 CD8A CD4 CCR6
31 latent syphilis 10.5 CD8A CD4
32 intestinal perforation 10.5 NKX2-1 KRT7 CD4
33 cecal disease 10.5 KRT7 CD4 CCR6
34 borst-jadassohn intraepidermal carcinoma 10.5 KRT7 CD8A CD4
35 iritis 10.5 CD8A CD4 CCR6
36 mucinous stomach adenocarcinoma 10.5 NKX2-1 KRT7 KIT
37 parapsoriasis 10.5 CD8A CD5 CD4
38 autoimmune cholangitis 10.5 CD8A CD4 CCR6
39 ceruminous adenocarcinoma 10.5 KRT7 KIT
40 sarcomatous intrahepatic cholangiocarcinoma 10.5 NKX2-1 KRT7 KIT
41 immunodeficiency 36 10.5 CD8A CD4 AKT1
42 lymphoepithelioma-like thymic carcinoma 10.5 KIT CD5
43 lung leiomyosarcoma 10.5 NKX2-1 KRT7 KIT
44 follicular mucinosis 10.5 CD8A CD5 CD4
45 uterus leiomyosarcoma 10.5 NKX2-1 KRT7 KIT
46 uterine corpus sarcoma 10.5 NKX2-1 KRT7 KIT
47 type 1 diabetes mellitus 23 10.5 CD8A CD4
48 viral pneumonia 10.5 CD8A CD4 CCR6
49 ovarian germ cell cancer 10.5 NKX2-1 KRT7 KIT
50 autoimmune lymphoproliferative syndrome, type iia 10.5 CD8A CD4

Graphical network of the top 20 diseases related to Thymus Cancer:



Diseases related to Thymus Cancer
Sources

Symptoms & Phenotypes for Thymus Cancer

About this section

Human phenotypes related to Thymus Cancer:

58 31 (show all 21)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 neoplasm of the thymus 58 31 hallmark (90%) Very frequent (99-80%) HP:0100521
2 immunodeficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002721
3 palpebral edema 58 31 frequent (33%) Frequent (79-30%) HP:0100540
4 dyspnea 58 31 frequent (33%) Frequent (79-30%) HP:0002094
5 cough 58 31 frequent (33%) Frequent (79-30%) HP:0012735
6 chest pain 58 31 frequent (33%) Frequent (79-30%) HP:0100749
7 mediastinal lymphadenopathy 58 31 frequent (33%) Frequent (79-30%) HP:0100721
8 diaphragmatic paralysis 58 31 frequent (33%) Frequent (79-30%) HP:0006597
9 dysgammaglobulinemia 58 31 frequent (33%) Frequent (79-30%) HP:0002961
10 ptosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000508
11 dysphagia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002015
12 increased intracranial pressure 58 31 occasional (7.5%) Occasional (29-5%) HP:0002516
13 autoimmunity 58 31 occasional (7.5%) Occasional (29-5%) HP:0002960
14 pericarditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001701
15 headache 58 31 occasional (7.5%) Occasional (29-5%) HP:0002315
16 abnormal bleeding 58 31 occasional (7.5%) Occasional (29-5%) HP:0001892
17 fatigable weakness 58 31 occasional (7.5%) Occasional (29-5%) HP:0003473
18 cardiac arrest 58 31 occasional (7.5%) Occasional (29-5%) HP:0001695
19 language impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0002463
20 neuroendocrine neoplasm 58 31 occasional (7.5%) Occasional (29-5%) HP:0100634
21 edema 58 Frequent (79-30%)

MGI Mouse Phenotypes related to Thymus Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.03 AIRE AKT1 AMPH CNTNAP2 DPYSL5 IL2
2 integument MP:0010771 9.81 AKT1 CD4 CD5 CD8A CNTNAP2 KIT
3 nervous system MP:0003631 9.8 AIRE AKT1 AMPH CCR6 CD4 CD5
4 normal MP:0002873 9.28 AIRE AKT1 CCR6 CD4 CD5 CD8A
Sources

Drugs & Therapeutics for Thymus Cancer

About this section

Drugs for Thymus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Tubulin Modulators Phase 4
2 Antimitotic Agents Phase 4
3
Etoposide Approved Phase 3 33419-42-0 36462
4 Etoposide phosphate Phase 3
5
Palbociclib Approved, Investigational Phase 2 571190-30-2 5005498 5330286 11431660
6
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
7
Octreotide Approved, Investigational Phase 2 83150-76-9 6400441 383414
8
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
9
Bevacizumab Approved, Investigational Phase 2 216974-75-3
10
Somatostatin Approved, Investigational Phase 2 38916-34-6, 51110-01-1 53481605
11
Pasireotide Approved Phase 2 396091-73-9 9941444
12
Nedaplatin Approved, Investigational Phase 2 95734-82-0
13
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
14
ramucirumab Approved, Investigational Phase 2 947687-13-0
15
nivolumab Approved Phase 2 946414-94-4
16
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
17
Plicamycin Approved, Investigational, Withdrawn Phase 1, Phase 2 18378-89-7 163659 163660 163661 163662 163663 163664
18
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
19
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
20
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
21
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
22
Pembrolizumab Approved Phase 2 1374853-91-4
23
Lenvatinib Approved, Investigational Phase 2 417716-92-8
24
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
25
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
26
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
27
Belinostat Approved, Investigational Phase 1, Phase 2 866323-14-0
28
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
29
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
30
Amrubicin Investigational Phase 2 110267-81-7
31
Lexatumumab Investigational Phase 2 845816-02-6
32
Molgramostim Investigational Phase 2 99283-10-0
33
Saracatinib Investigational Phase 2 379231-04-6
34
Maleic acid Experimental Phase 2 110-16-7 444266
35 Imatinib Mesylate Phase 2 220127-57-1 123596
36 Anti-Inflammatory Agents Phase 2
37 Gastrointestinal Agents Phase 2
38 glucocorticoids Phase 2
39 Hormone Antagonists Phase 2
40 Antineoplastic Agents, Hormonal Phase 2
41
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
42 Hormones Phase 1, Phase 2
43 Immunoglobulins, Intravenous Phase 2
44 Antibodies, Monoclonal Phase 2
45 Liver Extracts Phase 1, Phase 2
46 Calcium, Dietary Phase 1, Phase 2
47 Angiogenesis Inhibitors Phase 2
48 Albumin-Bound Paclitaxel Phase 2
49 Protein Kinase Inhibitors Phase 2
50 Antineoplastic Agents, Immunological Phase 2

Interventional clinical trials:

(show top 50) (show all 87)
# Name Status NCT ID Phase Drugs
1 Single-Arm Study to Carbo-paclitaxel/ Nab-paclitaxel Combined With Pembrolizumab as the First Line Therapy in Treating Patients With Locally Advanced or Metastatic Invasive Thymoma and Thymic Carcinoma That Cannot Be Removed by Surgery Recruiting NCT04554524 Phase 4 Chemotherapy+Pembrolizumab.
2 A Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic Carcinoma Recruiting NCT02633514 Phase 3 Cisplatin;Etoposide
3 A Multi-institutional, Randomized Controlled Trial of Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma Recruiting NCT02014805 Phase 3
4 An Open-label, Multi-center, Randomized Phase III Study of Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection Recruiting NCT02633553 Phase 3
5 Phase II Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Unknown status NCT03449173 Phase 2 Sunitinib
6 A Phase II Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumour (TET) Progressing After Primary Chemotherapy. Unknown status NCT03466827 Phase 2 Selinexor
7 Samsung Medical Center Unknown status NCT03219554 Phase 2 Palbociclib
8 Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma Completed NCT00010257 Phase 2 carboplatin;paclitaxel
9 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
10 Phase II Study of Octreotide Treatment of Advanced, Recurrent Thymoma Completed NCT00003283 Phase 2 octreotide acetate;prednisone
11 Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Completed NCT02049047 Phase 2 Everolimus
12 Phase II Study of Trimodality Therapy for Patients With Thymoma or Thymic Carcinoma at Significant Risk for Recurrence Completed NCT00387868 Phase 2 cisplatin and etoposide
13 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2 IMC-12
14 A Phase II Study of Erlotinib Plus Bevacizumab in the Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00369889 Phase 2 bevacizumab;Erlotinib
15 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2 Premetrexed (Alimta)
16 A Multicenter Phase II Study of Belinostat (PXD-101) in Previously Chemotherapy Treated Thymoma and Thymic Carcinoma Completed NCT00589290 Phase 2 Belinostat (PDX101)
17 A Phase II, Non-comparative, Open Label, Multi-center Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Completed NCT02623127 Phase 2 Sunitinib
18 Efficacy of Medical Treatment With Octreotide in Patients With Primary Inoperable Thymoma to Reduce Tumor Size Completed NCT00332969 Phase 2 Octreotide
19 Radiofrequency Ablation of Pulmonary Malignancy Completed NCT00024076 Phase 2
20 Surgical Cytoreduction Followed by Intraoperative Intrathoracic Hyperthermic Chemotherapy Perfusion for the Management of Disseminated Pleural Malignancies Completed NCT01163552 Phase 2
21 Efficacy and Safety of High Dose Regimen of Octreotide LAR in Patients With Neuroendocrine Tumors in Progressive Disease: A Phase II, Open, Multicentric Prospective Study Completed NCT00990535 Phase 2 Octreotide-LAR
22 Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size Completed NCT02021942 Phase 2 SOM230 LAR
23 A Phase II Study of LEE011 (Ribociclib) in Patients With Advanced Neuroendocrine Tumors of Foregut Origin Completed NCT02420691 Phase 2 Ribociclib
24 A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Completed NCT01364727 Phase 2 Amrubicin
25 A Prospective, Phase II Trial of Induction Chemotherapy With Docetaxel/Cisplatin for Masaoka Stage III/IV Thymic Epithelial Tumors Completed NCT01312324 Phase 2 neoadjuvant docetaxel/cisplatin
26 A Phase II Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Who Progressed After at Least One Previous Regimen of Cisplatin-Containing Chemotherapy Completed NCT02607631 Phase 2 Pembrolizumab
27 A Prospective, Phase â…¡ Study of Thymosin a1 During Chemoradiotherapy For Unresectable Thymoma and Thymic Carcinoma Recruiting NCT03663764 Phase 2 Thymosin a1
28 Improving Treatment Strategies in Thymic Epithelial Tumors: a TYME Collaborative Effort Recruiting NCT03921671 Phase 2
29 A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma Recruiting NCT04417660 Phase 2 M7824
30 Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Recruiting NCT03134118 Phase 2 Nivolumab
31 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
32 Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors Recruiting NCT03583086 Phase 1, Phase 2 VEGFR/PDGFR Dual Kinase Inhibitor X-82
33 A Phase 2, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN046 in Subjects With Thymic Carcinoma Recruiting NCT04469725 Phase 2 KN046
34 A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma Recruiting NCT03694002 Phase 2 Carboplatin;Paclitaxel
35 A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma Recruiting NCT03463460 Phase 2 Sunitinib Malate
36 An Open-Label, Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma Recruiting NCT04321330 Phase 2 Atezolizumab
37 Phase I/II Evaluation of Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases Recruiting NCT02859415 Phase 1, Phase 2 Mithramycin
38 A Phase II, Neo-adjuvant Pembrolizumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Pembrolizumab Consolidation Therapy in Locally Advanced Thymic Epithelial Tumor (TET) Recruiting NCT03858582 Phase 2 pembrolizumab
39 A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT) Recruiting NCT03193437 Phase 2 Open Label Selinexor
40 Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas Active, not recruiting NCT02364076 Phase 2 Pembrolizumab;Epacadostat
41 A Phase II Trial of Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (BMS #CA225-331/Lilly Trial Alias I4E-US-X007) Active, not recruiting NCT01025089 Phase 2 Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
42 A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy Active, not recruiting NCT01621568 Phase 2 Sunitinib
43 An Open-label Phase II Study of Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND Active, not recruiting NCT02307500 Phase 2 Regorafenib
44 A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic Carcinoma PaTIents. PECATI. Not yet recruiting NCT04710628 Phase 2 Pembrolizumab;Lenvatinib 10 mg
45 Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor Not yet recruiting NCT04667793 Phase 2 Toripalimab;Chemotherapy;Chemotherapy
46 Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors Not yet recruiting NCT04517539 Phase 2 rhGM-CSF，Peginterferon alfa-b2，radiation
47 A Phase II Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas Suspended NCT02220855 Phase 2 BKM120
48 A Phase II Study of Paclitaxel and Cisplatin in Previously Untreated, Unresectable Invasive Thymoma or Thymic Carcinoma Terminated NCT00818090 Phase 2 paclitaxel and cisplatin
49 Phase II Trial of AZD0530 for Patients With Relapsed/Refractory Thymic Malignancies (Thymoma and Thymic Carcinoma) Terminated NCT00718809 Phase 2 saracatinib
50 Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Previously Treated With Chemotherapy Terminated NCT01011439 Phase 2 Milciclib Maleate

Search NIH Clinical Center for Thymus Cancer

Cochrane evidence based reviews: thymus neoplasms

Sources

Genetic Tests for Thymus Cancer

About this section
Sources

Anatomical Context for Thymus Cancer

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Thymus Cancer:

19
Thymus

MalaCards organs/tissues related to Thymus Cancer:

40
Thymus, Lung, Liver, B Cells, Bone Marrow, Bone
Sources

Publications for Thymus Cancer

About this section

Articles related to Thymus Cancer:

(show all 45)
# Title Authors PMID Year
1
Immunotherapy vs platinum for advanced or metastatic thymic carcinoma: A protocol for systematic review and meta analysis. 42
33545943 2021
2
Recent advances and conceptual changes in the classification of neuroendocrine tumors of the thymus. 42
33555458 2021
3
Molecular pathology of thymomas: implications for diagnosis and therapy. 42
33674910 2021
4
De novo hepatocellular carcinoma in a non-cirrhotic allograft 27 years after liver transplantation: A case report. 61
33382179 2020
5
Trans-sternotomy versus video-assisted thoracic surgery for early-stage thymoma patients: a meta-analysis. 61
32420258 2020
6
Severe Aplastic Anemia Developed after Thymectomy: A Case Report and Literature Review. 61
32509363 2020
7
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). 61
29660598 2018
8
Thymic Carcinoma Associated with Cerebellar Degeneration. 61
30756016 2018
9
Diagnosis of Churg-Strauss Syndrome Presented With Neuroendocrine Carcinoma: A Case Report. 61
28758089 2017
10
Ribosomal Protein Rpl22 Controls the Dissemination of T-cell Lymphoma. 61
27197189 2016
11
[The anti-tumor mechanisms in long-lived rodents]. 61
27232489 2016
12
Sunitinib effective for rare thymus cancer. 61
25680712 2015
13
Gene mutation may signal indolent thymus cancer. 61
25185203 2014
14
Excessive risk of cancer and in particular lymphoid malignancy in myasthenia gravis patients: a population-based cohort study. 61
24332676 2014
15
Six cases report of differential diagnosis of periapical diseases. 61
21789964 2011
16
Spiradenoma reminiscent of thymoma: report of a case and review of the literature. 61
18647207 2009
17
Limited upper sternotomy in general thoracic surgery. 61
18368317 2008
18
Utility of immunohistochemistry in separating thymic neoplasms from germ cell tumors and metastatic lung cancer involving the anterior mediastinum. 54
12777991 2003
19
[Prevalence of the neuroendocrine phenotype in thymus neoplasms]. 61
12192931 2002
20
Immunohistochemical markers in the differentiation of thymic and pulmonary neoplasms. 54
11952859 2002
21
[The importance of magnetic resonance tomography in the detection of a thymus cancer. A case report]. 61
8303472 1993
22
[The diagnostic and treatment characteristics of myasthenia in thymus neoplasms]. 61
8329236 1993
23
Thymus cancer epidemiology in England and Wales. 61
2372494 1990
24
[Thymus neoplasms with myasthenic syndrome]. 61
6865224 1983
25
[Cytological changes in the tumor, bone marrow and leukoconcentrate of peripheral blood in thymus neoplasms]. 61
331673 1977
26
[Pathological anatomy of thymus neoplasms]. 61
1029800 1976
27
[Cushing's syndrome in thymus neoplasms structurally resembling carcinoid tumor]. 61
1208153 1975
28
[Problems of thymus neoplasms. Introductory remarks]. 61
1118302 1975
29
[Thymus neoplasms. Opening remarks]. 61
235118 1975
30
[Thymus neoplasms associated with myasthenia gravis]. 61
1118308 1975
31
[Morphological and biological particuliarities of thymus neoplasms]. 61
4603689 1974
32
[Thymus neoplasms. Clinical aspects, therapy and prognosis]. 61
4589046 1973
33
[Therapy of thymus neoplasms and of myasthenia gravis pseudoparalytica]. 61
4782941 1973
34
[Thymus neoplasms in children]. 61
4740635 1973
35
[On several cases of thymus neoplasms with a benign course]. 61
4791573 1973
36
[Thymus neoplasms]. 61
4678742 1972
37
[Myasthenia and thymus neoplasms]. 61
5020029 1972
38
[Acute mediastinal syndrome caused by malignant thymus neoplasms in children]. 61
5533435 1970
39
[Cytocaryological study on thymus neoplasms]. 61
5526168 1970
40
[Thymus neoplasms: clinical, pathological and radiological study on 40 patients]. 61
5442800 1970
41
[Paraneoplastic polyneuropathy in thymus cancer]. 61
5811275 1969
42
[Problems in the clinical diagnosis of thymus neoplasms]. 61
5637541 1968
43
[Thymus neoplasms in childhood]. 61
5759013 1968
44
[Myasthenia gravis in thymus neoplasms]. 61
5175158 1964
45
[The thymus & cancer]. 61
13524076 1958
Sources

Variations for Thymus Cancer

About this section

Cosmic variations for Thymus Cancer:

9 (show all 36)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM105695698 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 24
2 COSM142891951 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 24
3 COSM87975416 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 24
4 COSM142627127 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.259T>A p.Y87N 17:7675236-7675236 24
5 COSM121944830 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-21T>A p.? 17:7675236-7675236 24
6 COSM106116533 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 24
7 COSM144072853 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.343T>A p.Y115N 17:7675236-7675236 24
8 COSM144363948 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.259T>A p.Y87N 17:7675236-7675236 24
9 COSM122332176 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-21T>A p.? 17:7675236-7675236 24
10 COSM93250189 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 24
11 COSM145076506 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.259T>A p.Y87N 17:7675236-7675236 24
12 COSM122804157 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-21T>A p.? 17:7675236-7675236 24
13 COSM144718880 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.259T>A p.Y87N 17:7675236-7675236 24
14 COSM144140974 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-102T>A p.? 17:7675236-7675236 24
15 COSM112319052 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 24
16 COSM143214478 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-102T>A p.? 17:7675236-7675236 24
17 COSM143433019 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.259T>A p.Y87N 17:7675236-7675236 24
18 COSM111826108 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 24
19 COSM144005441 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-102T>A p.? 17:7675236-7675236 24
20 COSM103083119 SMAD4 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1081C>T p.R361C 18:51065548-51065548 24
21 COSM139771670 SMAD4 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.793C>T p.R265C 18:51065548-51065548 24
22 COSM91380576 SMAD4 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1081C>T p.R361C 18:51065548-51065548 24
23 COSM88596522 PREX2 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.107G>T p.R36L 8:67952501-67952501 24
24 COSM88408638 NOTCH2 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.3359G>A p.C1120Y 1:119937445-119937445 24
25 COSM87667907 KMT2D thymus,NS,thymic carcinoma,undifferentiated carcinoma c.12634C>T p.R4212W 12:49032071-49032071 24
26 COSM88314740 KIT thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1657T>A p.Y553N 4:54727425-54727425 24
27 COSM132270273 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2768C>T p.A923V 23:45078488-45078488 24
28 COSM101719617 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2870C>T p.A957V 23:45078488-45078488 24
29 COSM145420036 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.*1915C>T p.? 23:45078488-45078488 24
30 COSM143359668 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.3005C>T p.A1002V 23:45078488-45078488 24
31 COSM102181889 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2921C>T p.A974V 23:45078488-45078488 24
32 COSM132025397 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2714C>T p.A905V 23:45078488-45078488 24
33 COSM85170206 IL7R thymus,NS,thymic carcinoma,undifferentiated carcinoma c.537+1G>T p.? 5:35871214-35871214 24
34 COSM121730466 IL7R thymus,NS,thymic carcinoma,undifferentiated carcinoma c.537+1G>T p.? 5:35871214-35871214 24
35 COSM143857324 FAT1 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.12712A>G p.K4238E 4:186596834-186596834 24
36 COSM110448949 FAT1 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.12706A>G p.K4236E 4:186596834-186596834 24
Sources

Expression for Thymus Cancer

About this section
Search GEO for disease gene expression data for Thymus Cancer.
Sources

Pathways for Thymus Cancer

About this section

Pathways related to Thymus Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
ICos-ICosL Pathway in T-Helper Cell 63
Show member pathways
 12.16 IL2 ICOSLG CD4 AKT1
2
Cell adhesion molecules 36
11.91 ICOSLG CNTNAP2 CD8A CD4
3
Yersinia infection 36
11.81 IL2 CD8A CD4 AKT1
4
Hematopoietic cell lineage 36
11.55 KIT CD8A CD5 CD4
5
CTLA4 Signaling 63
11.48 CD8A CD4 AKT1
6
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.42 KIT IL2 CD8A CD5 CD4
7
Dendritic Cells Developmental Lineage Pathway 64
11.33 KIT IL2 CD8A CD4
8
Primary immunodeficiency 36
11.16 CD8A CD4 AIRE
9
T-Cell Receptor and Co-stimulatory Signaling 1
10.99 IL2 CD8A AKT1
10
Innate Lymphoid Cell Differentiation Pathways 64
10.92 KIT IL2 CD8A CD4 CCR6
Sources

GO Terms for Thymus Cancer

About this section

Cellular components related to Thymus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.1 KIT ICOSLG CD8A CD5 CD4 CCR6

Biological processes related to Thymus Cancer according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.85 IL2 CD8A CD4 CCR6 AIRE
2 positive regulation of protein phosphorylation GO:0001934 9.73 MUSK IL2 CD4 AKT1
3 positive regulation of cell growth GO:0030307 9.67 LGI1 IL2 AKT1
4 T cell costimulation GO:0031295 9.54 ICOSLG CD5 AKT1
5 T cell activation GO:0042110 9.5 ICOSLG CD8A CD4
6 cellular response to granulocyte macrophage colony-stimulating factor stimulus GO:0097011 9.48 CD4 AKT1
7 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.46 MUSK KIT CD8A CD4
8 T cell differentiation GO:0030217 9.43 KIT IL2 CD4
9 positive regulation of gene expression GO:0010628 9.43 TTN NKX2-1 MUSK MIR125A KIT AKT1
10 skeletal muscle acetylcholine-gated channel clustering GO:0071340 9.4 MUSK LRP4
11 positive regulation of kinase activity GO:0033674 8.92 MUSK KIT IL2 CD4

Molecular functions related to Thymus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 TTN NKX2-1 MUSK LRP4 LGI1 KRT7
2 enzyme binding GO:0019899 9.02 TTN NKX2-1 CNTNAP2 CD4 AKT1
Sources

Sources for Thymus Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....